A business waiting on a national decision

Feedback plc (LSE:FDBK), the clinical software group behind the Bleepa collaboration platform, enters the final quarter of 2026 with its prospects tied closely to a single decision by NHS England. In a trading update published on 14 July 2026, the company said it was hopeful of a ruling on a potential national contract "around the calendar year end", while stressing that the timing sits outside its control because NHS England and HM Treasury still need to complete their evaluation.

What the company does

Feedback describes itself as a clinical infrastructure specialist. Its main product, Bleepa, is a platform that allows clinicians and care teams to work asynchronously on patient pathways, with the aim of reducing unnecessary outpatient appointments and speeding up decisions. The software is sold on a software-as-a-service basis to NHS trusts and other health and care organisations.

Latest developments

The July update covered the year ended 31 May 2026. On an unaudited basis, revenue was roughly flat at about £0.8m, compared with £0.9m a year earlier. The company said its EBITDA loss was smaller than both expectations and the previous year, reflecting cost controls and cash management. Year-end cash stood at £2.7m, ahead of expectations, and management said this provides runway into mid-2027.

Operationally, Feedback reported that integration with the NHS e-Referral Service had led to a tenfold increase in GP practices referring into Bleepa within weeks. It also completed integrations with Patients Know Best and the Evolve electronic medical record, and released version 1.7 of Bleepa. In Sussex, the company said all breathlessness patients over a three-month period had been diverted away from outpatient appointments, while an insomnia pathway has been rolled out across Kent, Surrey and Sussex.

These updates followed an April 2026 announcement in which the company said a central NHS decision, previously expected around the end of March, had been pushed back by at least six to nine months. At the same time, NHS England extended Bleepa licences at Queen Victoria Hospital, which carry an annualised contract value of £495k, to December 2026. Feedback also agreed a further annual extension with Northern Care Alliance NHS Foundation Trust.

Financial picture

The company remains loss-making and relatively small. For the year to 31 May 2025, it reported revenue of £0.89m and a loss after tax of £7.32m, which included a one-off impairment of £3.19m. It raised about £6.1m gross in November 2024. Management has since cut its activity in India, reduced its Polish development team and pursued further savings. No dividend has been reported.

Sector and index context

Feedback sits within the healthcare technology segment of the FTSE AIM All Share Index, a part of the market where companies selling to the NHS often face long procurement cycles and funding uncertainty. The company has pointed to elective recovery as a tailwind: NHS waiting lists peaked at 7.77 million in September 2023 and had fallen by 550,000 by April 2026, according to figures cited in its update.

Key risks

The most obvious risk is concentration. A large part of the investment case rests on a national contract whose timing has already slipped once. Revenue remains modest relative to costs, so any further delay would place more weight on the existing cash runway. Restructuring within NHS England adds another layer of uncertainty, and the company has said it may selectively explore alternatives to create shareholder value.

What to watch next

Investors are likely to focus on any news from NHS England on the national Bleepa opportunity around the turn of the year, the renewal of the Queen Victoria Hospital licences beyond December 2026, and audited full-year results. Cash burn will also be closely followed.